Evidence map›Paper›PMID 28232611›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2017

Pharmacokinetic Analysis of Dynamic

Jazmin Schwartz, Milan Grkovski, Andreas Rimner, Heiko Schöder, Pat B Zanzonico, Sean D Carlin, Kevin D Staton, John L Humm, Sadek A Nehmeh

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Prospective Evaluation of a Tumor Control Probability Model Based on DynamicJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  3. Review
  4. Article
  5. Article
  6. Kinetic Evaluation of the Hypoxia Radiotracers [Nuclear medicine and molecular imaging · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Hypoxia and the phenomenon of immune exclusion.Journal of translational medicine · 2021
    Review
  11. Review
  12. Review
  13. Article
  14. Quasi-Resonance Signal Amplification by Reversible Exchange.The journal of physical chemistry letters · 2018
    Article
  15. Oxygen Sensing, Hypoxia Tracing andFrontiers in chemistry · 2018
    Review
  16. [EJNMMI research · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jazmin SchwartzDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York schwarj1@mkscc.org.
Milan GrkovskiDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Andreas RimnerDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Heiko SchöderDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and.
Pat B ZanzonicoDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Sean D CarlinDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and.
Kevin D StatonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and.
John L HummDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Sadek A NehmehNational Center for Cancer Care and Research, Doha, Qatar.
Memorial Sloan Kettering Cancer Center · USNational Center for Cancer Care and Research · QA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Hypoxic tumors exhibit increased resistance to radiation, chemical, and immune therapies.

Indexed as

Models, BiologicalAgedAged, 80 and overCarcinoma, Non-Small-Cell LungComputer SimulationFemaleHumansLung NeoplasmsMaleMetabolic Clearance RateMiddle AgedMisonidazolePositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsSensitivity and SpecificityfluoromisonidazoleMisonidazoleRadiopharmaceuticals18F-fluoromisonidazolecompartmental analysishypoxianon-small cell lung cancerpharmacokinetic analysis

Identifiers

PMID28232611
PMCPMC5450365
OpenAlexW2589848716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.